Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Dermatology and Therapy
|
June 25, 2026
Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis
Gil Yosipovitch, Katarzyna Borkowska, James Frampton, et al.
Behavioural Pharmacology
|
May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
Ramakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
June 14, 2020
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H<sub>3</sub>R) inverse agonist in clinical development for the treatment of narcolepsy
Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, et al.
Psychopharmacology
|
February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Ramakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
The Journal of Dermatological Treatment
|
October 27, 2024
Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany
Nicholas Durno, Pablo Arija, Krystallia Pantiri, et al.
Journal of Medicinal Chemistry
|
September 26, 2012
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Anand Daulatabad, et al.
Journal of Medicinal Chemistry
|
February 7, 2020
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
European Journal of Medicinal Chemistry
|
September 13, 2015
Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Drug Development
Ramakrishna Nirogi, Renny Abraham, Jyothsna Ravulu, et al.
Dermatology and Therapy
|
June 25, 2026
Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis
Gil Yosipovitch, Katarzyna Borkowska, James Frampton, et al.
Behavioural Pharmacology
|
May 31, 2018
SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
Ramakrishna Nirogi, Renny Abraham, Vijay Benade, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
June 14, 2020
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H<sub>3</sub>R) inverse agonist in clinical development for the treatment of narcolepsy
Ramakrishna Nirogi, Gopinadh Bhyrapuneni, Nageswara Rao Muddana, et al.
Psychopharmacology
|
February 7, 2021
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
Ramakrishna Nirogi, Vijay Benade, Saivishal Daripelli, et al.
The Journal of Dermatological Treatment
|
October 27, 2024
Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany
Nicholas Durno, Pablo Arija, Krystallia Pantiri, et al.
Journal of Medicinal Chemistry
|
September 26, 2012
Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists
Ramakrishna Nirogi, Anil Shinde, Anand Daulatabad, et al.
Journal of Medicinal Chemistry
|
February 7, 2020
Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine α4β2 Receptor Antagonist for the Treatment of Depression
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Journal of Psychopharmacology (Oxford, England)
|
February 6, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Ramakrishna Nirogi, Venkata R Grandhi, Rajesh B Medapati, et al.
European Journal of Medicinal Chemistry
|
September 13, 2015
Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil K Shinde, et al.
Page
of 3